Molecure reports lower half-year loss, with Molecure stock valued at PLN 157.0 million

Published on 10/15/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Net loss fell to PLN 6.31 million in the first half of 2026. Molecure stock costs EUR 1.44 on October 15, 2026, with PLN 157.0 million market value.

Clinical progress and financial discipline

Molecure reduced its first-half 2026 net loss to PLN 6.31 million on September 30, 2026.
More than 40 patients had been randomized in the OATD-01 study by September 30, 2026.
Molecure stock trades at EUR 1.44 at 1:43 p.m. CEST at Lang & Schwarz on October 15, 2026.
The next quarterly report is scheduled for October 30, 2026.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure (PLONCTH00011) reported a PLN 6.31 million net loss for the first half of 2026, down from PLN 8.52 million a year earlier, according to Molecure on September 30, 2026. The clinical-stage biotechnology company also reported more than 40 randomized patients in its OATD-01 study, making recruitment progress the key operating signal.

Half-year figures sharpen the story

Operating revenue fell to PLN 1.86 million in the first half of 2026 from PLN 3.52 million in the first half of 2025. The decline was mainly linked to lower grant income, while operating costs fell to PLN 8.20 million from PLN 12.65 million, a reduction of PLN 4.45 million, according to BiznesRadar. Cash stood at PLN 24.91 million on June 30, 2026, compared with PLN 16.35 million at the end of 2025.

What does the trial timeline show?

The KITE Phase II study of OATD-01 reached 30 enrolled patients during the first half of 2026, enabling its first planned interim analysis. In July 2026, the Independent Data Monitoring Committee recommended continuing the study without protocol changes. Molecure was targeting randomization of 50 patients in the following months, after which a second interim analysis is planned, according to Molecure. The study remains blinded, so the early biomarker trends are not a clinical efficacy result.

Three clinical milestones since March

The company raised PLN 20.12 million net through its Series K share issue in March 2026. On May 28, 2026, the first patient received the 80 milligram daily dose in the OATD-02 Phase I study. On September 30, 2026, Molecure reported more than 40 randomized patients in OATD-01 and two patients completing safety observation at the 80 milligram dose, as stated in the Molecure release.

What dates come next?

Molecure's investor calendar sets October 30, 2026, for publication of its third-quarter 2026 report and November 9 to November 11, 2026, for BIO Europe in Cologne. The dates are listed on the company's investor overview. These milestones put the next financial update ahead of the next major partnering event.

Market value and trading

Molecure's primary listing is on the Warsaw Stock Exchange, where the stock was last at PLN 6.35 at 1:35 p.m. CEST on October 15, 2026. Its market capitalization was PLN 157.0 million, and the 52-week range stood at PLN 4.98 to PLN 9.04. At Lang & Schwarz, Molecure stock was trading at EUR 1.44 on October 15, 2026 at 1:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Molecure stock.